DrugPatentWatch Database Preview
Drugs in Development Information for Huperzine A
» See Plans and Pricing
What is the development status for investigational drug Huperzine A?
Huperzine A is an investigational drug.
There have been 12 clinical trials for Huperzine A.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Intracranial Hemorrhage, Hypertensive. The leading clinical trial sponsors are Biscayne Neurotherapeutics, Inc., Melbourne Health, and National Institute on Aging (NIA).
Summary for Huperzine A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 863 |
| WIPO Patent Applications | 1,252 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2016-11-01) |
| Vendors | 98 |
Recent Clinical Trials for Huperzine A
| Title | Sponsor | Phase |
|---|---|---|
| Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 |
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Biscayne Neurotherapeutics Australia Pty, Ltd. | Phase 1/Phase 2 |
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Biscayne Neurotherapeutics, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Huperzine A
Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A
US Patents for Huperzine A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
